Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | |||
| Small Cell Lung Cancer (SCLC) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Treatment patterns | Through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and prevalence | Through study completion, an average of 1 year | |
| Baseline demographic and clinical characteristics | Through study completion, an average of 1 year | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Study population will comprise patients with lung cancer diagnosed after January 1, 2018 in the administrative databases for Alberta and Ontario.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| AstraZeneca Clinical Study Information Center | Contact | 1-877-240-9479 | information.center@astrazeneca.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Recruiting | Calgary | Alberta | T2N1N4 | Canada | |
| Research Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Overall survival |
| Through study completion, an average of 6 months |
| Time to/on therapy | Through study completion, an average of 6 months |
| Attrition rates | Through study completion, an average of 1 year |
| Healthcare resource utilization (HCRU) | Through study completion, an average of 1 year |
| Direct healthcare costs | Through study completion, an average of 1 year |
| Recruiting |
| Toronto |
| Ontario |
| M5T3M6 |
| Canada |
| D008171 |
| Lung Diseases |
| D012140 | Respiratory Tract Diseases |